Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFER-HF: IV vs Oral Iron in HFpEF
NCT03833336Phase 3Completed
- Sponsor
- IRBLleida
- Start
- Aug 2017
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric carboxymaltose, ferroglycine sulfate, sucrosomial iron in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by IRBLleida. Started Aug 2017; status: completed.
02
Drugs
ferric carboxymaltoseferroglycine sulfatesucrosomial iron
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03833336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833336.